New bladder cancer treatment aims to stop recurrence
NCT ID NCT07207824
Summary
This study is testing whether adding a targeted drug called disitamab vedotin to the standard BCG treatment works better for controlling high-risk, early-stage bladder cancer. It will involve about 182 patients whose cancer has been surgically removed but is at high risk of returning. Half will receive the new drug combination, while the other half will receive standard BCG treatment alone, to see which approach keeps patients cancer-free longer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER (UROTHELIAL, TRANSITIONAL CELL) CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200230, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.